Cryoport, Inc. (NASDAQ:CYRX) Short Interest Update

Cryoport, Inc. (NASDAQ:CYRX) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 4,430,000 shares, an increase of 9.1% from the March 31st total of 4,060,000 shares. Based on an average daily volume of 445,600 shares, the days-to-cover ratio is currently 9.9 days. Currently, 9.4% of the shares of the company are short sold.

Analyst Ratings Changes

CYRX has been the topic of a number of recent analyst reports. Needham & Company LLC dropped their price target on shares of Cryoport from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, March 13th. Stephens reiterated an “equal weight” rating and set a $17.00 price target on shares of Cryoport in a research note on Wednesday, March 13th. Jefferies Financial Group initiated coverage on shares of Cryoport in a research note on Thursday, April 4th. They set a “buy” rating and a $21.00 price target on the stock. Finally, UBS Group boosted their price target on shares of Cryoport from $14.50 to $17.00 and gave the stock a “neutral” rating in a research note on Friday, March 15th. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $18.63.

Insider Buying and Selling at Cryoport

In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the transaction, the director now directly owns 43,187 shares in the company, valued at $633,985.16. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Cryoport news, Director Ramkumar Mandalam sold 3,217 shares of Cryoport stock in a transaction on Friday, March 15th. The shares were sold at an average price of $14.68, for a total value of $47,225.56. Following the transaction, the director now directly owns 43,187 shares in the company, valued at $633,985.16. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Jerrell Shelton sold 2,631 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $17.54, for a total transaction of $46,147.74. Following the transaction, the chief executive officer now owns 692,182 shares in the company, valued at $12,140,872.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 73,940 shares of company stock worth $1,147,538. 10.10% of the stock is owned by company insiders.

Institutional Trading of Cryoport

Several institutional investors and hedge funds have recently modified their holdings of CYRX. Natixis Investment Managers International lifted its holdings in shares of Cryoport by 61.5% in the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock valued at $70,000 after purchasing an additional 1,727 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Cryoport by 13.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,462 shares of the company’s stock valued at $157,000 after purchasing an additional 1,395 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Cryoport in the third quarter valued at about $163,000. Pathstone Family Office LLC purchased a new stake in shares of Cryoport in the third quarter valued at about $165,000. Finally, Quantbot Technologies LP lifted its holdings in shares of Cryoport by 109.0% in the third quarter. Quantbot Technologies LP now owns 12,838 shares of the company’s stock valued at $176,000 after purchasing an additional 6,694 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Cryoport Stock Up 3.8 %

CYRX stock opened at $16.81 on Thursday. The company has a market cap of $826.38 million, a P/E ratio of -7.64 and a beta of 1.60. Cryoport has a 52 week low of $9.00 and a 52 week high of $24.17. The company’s 50-day moving average price is $16.90 and its 200 day moving average price is $15.06. The company has a current ratio of 11.73, a quick ratio of 11.16 and a debt-to-equity ratio of 0.82.

Cryoport (NASDAQ:CYRX) last released its quarterly earnings data on Tuesday, March 12th. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.19). The company had revenue of $57.26 million for the quarter, compared to analysts’ expectations of $58.27 million. Cryoport had a negative return on equity of 11.86% and a negative net margin of 42.69%. On average, research analysts expect that Cryoport will post -1.31 earnings per share for the current fiscal year.

About Cryoport

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.